







Multiple-Organ Heart Transplantation


Valluvan Jeevanandam, MD Director, Heart and Vascular Center Cynthia Chow Professor of Surgery Section Chief, Cardiac Surgery














Cardiac transplantation: recipient criteria (general) Maximum oxygen consumption VO₂<12 cc/kg/min Malignant intractable arrhythmias Inoperable ischemia Debilitated life style


Cardiac transplantation: recipient criteria (specifi	с)
 Age: 0-70 years, program specific Reversible pulmonary hypertension with PVR<6 woods units Malignancy: disease free for 5 years No active infection (HIV??) No pulmonary infarction or CVA within 6 weeks No active alcohol or drug abuse Not obese (BMI<36) No irreversible end organ damage from diabetes <i>No significant liver/renal/pulmonary disease which could decrease lifespan</i> Compliance Insurance 	
With FOREFRONT Heart & Vascular Multiple-organ Heart & Center	eart Transplantation 8




```
9
```







OHT-Implantation



13

Tricuspid annuloplasty

Right heart dysfunction primary effect of rejection and/or

preservation injury


- · Leads to tricuspid regurgitation
 - renal dysfunction
 - long term residual effect with decreased survival
- TR treated with annuloplasty or replacement

Randomized study of prophylactic tricuspid annuloplasty –

Jeevanadam V, Russell H, Mather P, Furukawa S, Anderson A, Raman J. 2006. Donor tricuspid annuloplasty during orthotopic heart transplantation: long-term results of a prospective controlled study. The Annals of Thoracic Surgery 82(6):2089-95



Multiple-organ Heart Transplantation 14




Results - summary


- Improves RV performance : Perioperative period (0-7days)
 - Shorter reperfusion time
 - Lower CVP, higher mPA-CVP difference
 - Lower mortality
 - Less TR overall and less % with >moderate TR
- 5 years

•


- Less TR
- Less progression in TR
- Fewer pts with >moderate TR
 - Improved renal function
 - Lower creatinine
 - Smaller increase in creatinine from baseline values
- Helps survive major hemodynamically compromising rejection
- UCMC significant TR 2.9% vs reported 20-40%

Multiple-organ Heart Transplantation 16







sternal fixa	tS - Song DH, Agarwal JP, Jeeva ation in the cardiac transplant pop nd Cardiovascular Surgery 126(3)	oulation. The Journal of	
Retro	spective Comparison (J	July 2000-July. 2004):	
	Total OHT Procedures	s n= 120 🚬	
	Total high risk OHT	n= 72	
issues	High Risk Patients	Post-op sternal	
	Wire Closure n= 42	7 (16.7%)	
	Plate Closure n= 30	0	
	Heart & Vascular Center		Multiple-organ Heart Transplantation 19







 Tacromilus/ CellCept / steroids Excellent results Survival 		
 1 yr: 85-90% 5 yr: 70-75% 90% return to work 95% NYHA class 1 or 2 	10yr: 65%	
 Complications due to imm 	unological barrier	


























Heart-Liver Transplant		
• Why?		
 HT or any Cardiac Surger mortality 	y in patients with cirrhosis	bad idea – 50%
 MELD score >13 genera surgery 	ally considered contraindication	on to cardiac
 Complications: bleeding dysfunction 	, vasoplegia, infection, prima	ry graft
 LT with cardiac dysfunction especially RV 	n bad idea – huge stress o	n heart,
LT with intra-transplant I	ECMO support possible	
 Indications 		
 Infiltrative – Amyloid 		
Congestive hepatopathy		
Congenital – failed Fontan	Tricuspid Regurgitation/stenosis	LV Failure
Constrictive pericarditis	RV failure	Cardiac tumor
UChicago Medicine Heart & Vascular Center		Multiple-organ Heart Transplantation 31




Heart-Liver Transplant – surgical technique
 HT followed by delayed different donor LT – bad idea, loss between transplants HLT same donor, liver first Indications: high PRA Issues: 1) Need to support heart during LT 2) Prolonged HT ischemic time Significantly higher risk for mortality – aHR 2.44 HLT same donor, simultaneous Indications: decrease liver ischemic time, eliminate IVC anastomosis, decrease antibody
 Indications: decrease internschemic time, eliminate into anastomosis, decrease antibody exposure Cumbersome, especially for complex reoperations Mortality aHR 1.39 HLT same donor, heart first (UCMC preference) Coordination between HT and LT teams to minimize ischemic times Heart dissection must be finished by the time organ arrives Liver back table preparation at time of final heart anastomosis
Weight The ForeFront Heart & Vascular 33 Multiple-organ Heart Transplantation 33


Heart-Liver Transplant – surgical technique	
 HLT same donor, heart first (UCMC preference) HT must be hemostatic and without complications Normal inotropes Completely reverse heparin – ready to close Place on ECMO (CentraMag) via femoral vein, SVC and aorta 3 L/Min, maintain inotropes Liver team proceeds without anti-coagulation for ECMO Increase ECMO flow during times of hemodynamic instability After LT, wean off ECMO De-cannulate, close with plates Liver team closes Immunosuppression: tacrolimus, CellCept, Steroids 	
Complications: 1)bleeding 2) Liver perfusion 3) Bile ducts abscess 5) Wound healing	4) Intra-abdominal
VI THE FOREFRONT VIChicago Medicine Heart & Vascular Center 24	Multiple-organ Heart Transplantation 34
























UCM Heart Transplant Program

- SRTR nationwide report (dates: 1/18 7/20)
- Best survival
- Shortest wait times

Table B10. Time to transplant for waiting list candidates* Candidates registered on the waiting list between 01/01/2015 and 06/30/2020

	7.2021
--	--------

	Percentile	Center	Months to T OPO/DSA	ransplant** Region	U.S.
	5th	0.2	0.2	0.3	0.2
	10th	0.2 0.5 1.1 2.8	0.4 1.1 5.6 Not Observed	0.4 1.6 9.5 Not Observed	0.4 1.2 6.2 Not Observed
	25th				
	50th (median time to transplant)				
	75th				
	Percentile	Center	Months to OPO/DSA	Transplant** Region	U.S.
	5th	0.1	0.2	0.2	0.2
	10th	0.2	0.3	0.4	0.3
	25th	0.4	1.0	1.3	1
AT THE FOREFRONT	50th (median time to transplant)	(0.9)	4.5	7.4	5.5
UChicago Heart & Vascular	75th	2.5	Not Observed		
Medicine Center			Multip	ne-organ meart	ттапярнанскион



Multiple Organ Heart Transplantation

- HL, HK, HLK performed with excellent results
- Highest status organ pulls other
 Forced sharing within 500 miles will help
- Survival equivalent or better than HT alone
- · Dedicated, daring Team
- Needs tremendous coordination and institutional commitment
- High risk, high resource utilization and so rewarding



UChicago Medicine Heart & Vascular Center



Multiple-organ Heart Transplantation 45

